TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00744406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy
Description: All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (sertraline ,paroxetineor or venlafaxine)
Description: Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
Study: NCT00448812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty with the Alair System
Description: Treatment of airways with the Alair System (Bronchial Thermoplasty) in the PREDECESSOR STUDY (NCT00214526).
Study: NCT01819844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop blood glucose control
Description: The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose \> 2 u/kg).
Study: NCT00771979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
Study: NCT03071679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omignan 1%, 2.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod 15mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan 1% and Imiquimod
Description: Omiganan 1% and Imiquimod

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan 2.5% and Imiquimod
Description: Omiganan 2.5% and Imiquimod

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study: NCT02425202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Post-operative continuous infusion until 0600 the next day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: Post-operative continuous infusion until 0600 the next day
Study: NCT02269254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Persona PS Knee Prosthesis by Zimmer
Description: Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen PS Knee Prosthesis by Zimmer
Description: Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
Study: NCT01055080

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk formula
Description: Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow's milk formula
Description: Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk formula
Description: Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
Study: NCT01551706

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ENI Patented Whole Grape Extract
Description: ENI Patented Whole Grape Extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02624622

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine application to cord by mother

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine application by CHW
Study: NCT02184910

Intervention type: DRUG
Intervention: pepsinogen and gastrin
Study: NCT04148898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Treatment of LM With osimertinb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Treatment of LM With osimertinb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment of LM With osimertinb combined with bevacizumab
Study: NCT03748121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama assisted trauma-focused Cognitive Behavioral Therapy (TF-CBT)
Description: The pranayama intervention is placed directly at the begin of the respective TF-CBT unit and will be repeated for 10 subsequent TF-CBT units. Pranayama contains the performance of Kapalabhati, Ujjayi, and/or Nadi Shodhana (for overall 1 minute) as well as following Kumbhaka (intentional respiratory reflex inhibition). Pranayama will be repeated 3 times before each TF-CBT unit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
Description: Trauma-focused Cognitive Behavioral Therapy (TF-CBT)
Study: NCT04938414

Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar puncture
Description: Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar puncture
Description: Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test
Study: NCT03056365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Nurse (AN)
Description: Protocoled AN-based management of detox

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Practitioner (GP)
Description: 'As usual' medical management of detox
Study: NCT00392496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study: NCT02143167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-fampridine
Description: One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-fampridine
Description: One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03201393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone and acetaminophen combination
Description: Twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day
Study: NCT00221039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen+ECP
Description: UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
Study: NCT02169388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Microbial composition using probiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo（for probiotic）
Description: microbiota modulation using placebo
Study: NCT01123772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-8875
Description: eye drops for 14 days in one eye

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Matched placebo
Study: NCT02260349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green infusion
Description: intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
Study: NCT00805519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine and chondroitin sulfate
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine and chondroitin sulfate plus Prednisolone
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine and Chondroitin sulfate plus Chloroquine
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
Study: NCT00912106

Intervention type: OTHER
Intervention: Synovial fluid composition and lubrication analysis
Description: Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
Study: NCT01790152

Intervention type: OTHER
Intervention: Assessment of Therapy Complications
Description: Ancillary studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00865579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide
Description: The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning.
Study: NCT01162122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)
Description: one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted trivalent subunit influenza vaccine (TIV)
Description: one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
Study: NCT03597139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin Ophthalmic Solution
Description: Investigational Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis®
Description: Comparator
Study: NCT00357890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy
Description: CSII initiated within 1 month of diagnosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily injections using insulin glargine + rapid acting analog
Description: MDI as control
Study: NCT05211141

Intervention type: DEVICE
Intervention: HLS KneeTec Deep Dish
Description: total knee arthroplasty with HLS KneeTec Deep Dish prosthesis
Study: NCT02923193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medtronic IN.PACT (DCB)
Description: The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
Study: NCT00076258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSRI + LD
Description: Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
Study: NCT02923193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic IN.PACT (DCB)
Description: The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
Study: NCT03293069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: the placebo twice daily morning and evening.
Study: NCT03128528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10mg
Description: Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor.
Study: NCT00569192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.135mg MAP0010
Description: 0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg MAP0010
Description: 0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered by nebulization twice daily for 12 weeks
Study: NCT04765410

Intervention type: DIAGNOSTIC_TEST
Intervention: EUS FNA (endoscopic ultrasound fine needle aspiration)
Description: Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will receive EUS FNA (endoscopic ultrasound fine needle aspiration).
Study: NCT00076258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSRI + PHD
Description: Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
Study: NCT03322436

Intervention type: DIAGNOSTIC_TEST
Intervention: HeartLinc kit
Description: Samples are collected and analyzed afterwards
Study: NCT04622202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: oral capsule pregabalin 150 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: multivitamin
Description: oral placebo in the form of oral multivitamin capsule.
Study: NCT02111681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calypso Beacon Implantation
Description: Bronchoscopic Calypso Beacon Implantation
Study: NCT02518841

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermaWedge TM
Description: ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThermaWedge TM
Description: ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Achilles Tendon Stretching
Description: Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Achilles Tendon Stretching
Description: Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
Study: NCT03527862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment according to lung ultrasonography
Description: Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
Study: NCT01824121

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: stem cell therapy
Description: Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: stem cell therapy
Description: Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
Study: NCT03193034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cementless Total Knee Arthroplasty
Description: Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
Study: NCT02194764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and 2-butanol
Description: 50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)
Description: a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
Study: NCT01683877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FloSeal application
Description: After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery
Description: After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
Study: NCT01583270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan
Description: Porridge rich in arabinoxylan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rye kernel
Description: Porridge made of rye kernels

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arabinoxylan and rye kernels
Description: Porridgde made of rye kernels and arabinoxylan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Semolina
Description: Semoline porridge. control meal.
Study: NCT04122755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA-1000
Description: Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA-1000
Description: Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA-1000
Description: Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA-1000
Description: Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.
Study: NCT02910843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: * Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~* Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.